Evidence map›Paper›PMID 38803385›Full record

ArticleJAC-antimicrobial resistance2024

Ceftaroline fosamil treatment patterns and outcomes in adults with community-acquired pneumonia: a real-world multinational, retrospective study.

Alex Soriano, Matteo Bassetti, Charalambos Gogos, Tristan Ferry, Raul de Pablo, Wajeeha Ansari, Michal Kantecki, Bernd Schweikert, Gustavo Luna, Francesco Blasi

Abstract read
In one paragraph

Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Towards a holistic approach to pulmonary infections. Insights from the Sixth Annual Meeting of Spanish Experts 2024.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alex SorianoInfectious Diseases Department, Hospital Clínic de Barcelona, CIBERINF, CIBER in Infectious Diseases, Barcelona, Spain.ORCID https://orcid.org/0000-0002-9374-0811
Matteo BassettiInfectious Diseases, Clinica Malattie Infettive, Ospedale Policlinico IRCCS San Martino and University of Genoa, Genoa, Italy.
Charalambos GogosDivison of Infectious Diseases, Department of Internal Medicine, University of Patras, Patras, Greece.
Tristan FerryInfectious Diseases Department, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France.
Raul de PabloDepartment of Intensive Care, Hospital Universitario Ramón y Cajal, IRYCIS, University of Alcalá, Madrid, Spain.
Wajeeha AnsariPfizer Biopharmaceuticals Group, Pfizer, New York, NY, USA.ORCID https://orcid.org/0000-0002-1910-5836
Michal KanteckiGlobal Medical Affaris, Pfizer, Paris, France.
Bernd SchweikertHealth Economics and Epidemiology, ICON plc, Munich, Germany.
Gustavo LunaHealth Economics and Epidemiology, ICON plc, Stockholm, Sweden.
Francesco BlasiRespiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This multicentre, observational, retrospective chart review study assessed ceftaroline fosamil treatment patterns and outcomes in adults hospitalized with community-acquired pneumonia (CAP) in usual care settings. Methods: Anonymized patient data were extracted from hospital records of adults with CAP who received ≥4 consecutive IV ceftaroline fosamil doses at sites in Brazil, Colombia, France, Greece, Italy, Russia and Spain. Results: The dataset included 185 patients (58.9% male; mean age 62.2 years), of whom 128 (69.2%) had severe CAP defined by CURB-65, PSI/PORT score or physician judgement. Conclusions: Ceftaroline fosamil was effective in treating adults with CAP, including severe CAP, in Europe and Latin America. Clinical response to ceftaroline fosamil was associated with reductions in healthcare resource use compared with non-responders.

Identifiers

PMID38803385
PMCPMC11128847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.